Status:
COMPLETED
Analysis of Expression of Specific Markers in Hepatocellular Carcinoma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these....
Eligibility Criteria
Inclusion
- The patient had pathologically proven hepatocellular carcinoma
- All the data required are available from patient's records
- A sufficient amount of RNA is available for all three tissue samples
Exclusion
- N/A
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00858000
Start Date
July 1 2009
End Date
December 1 2009
Last Update
December 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Florence, Tuscany, Italy, 50134